ACE2 and COVID-19: Several of these agents (NKG2D-ACE2 CAR-NK cells, anti–PD-1, IL-7) are either in active clinical trials or in the planning stages for COVID-19 (NCT04324996, NCT04356508, NCT04379076, respectively).